MEF2C and acute myeloid leukemia: Targeting LKB1 or SIK3 decreases histone acetylation at MEF2C-bound enhancers and suppresses AML proliferation, highlighting a novel strategy of disabling an oncogenic transcription factor by targeting its upstream kinases.